Scan to Download
One power score. Smarter investment decisions
China SXT Pharmaceuticals Inc
SXTC1.950USD
+0.050+2.63%
收盘 09/19, 16:00（美东）报价延迟15分钟
USD0.000盘后交易 (美东)
26.84M总市值
--市盈率 TTM
单季报
单季报+年报
单季报
年报
YOY
隐藏空白行
FY2025H1
FY2024H2
FY2024H1
FY2023H2
FY2023H1
FY2022H2
FY2022H1
FY2021H2
FY2021H1
FY2020H2
FY2020H1
FY2019H2
FY2019H1
FY2018Q4
FY2017Q4
营业总收入
-11.72%829.49K
29.54%988.91K
-22.24%939.58K
-51.52%763.39K
17.58%1.21M
71.70%1.57M
-73.38%1.03M
-52.90%917.07K
20.07%3.86M
-37.07%1.95M
-17.93%3.22M
--3.09M
--3.92M
24.40%1.43M
--1.15M
营业收入
-11.72%829.49K
29.54%988.91K
-22.24%939.58K
-51.52%763.39K
17.58%1.21M
71.70%1.57M
-73.38%1.03M
-52.90%917.07K
20.07%3.86M
-37.07%1.95M
-17.93%3.22M
--3.09M
--3.92M
24.40%1.43M
--1.15M
主营业务成本
6.68%694.74K
69.47%723.28K
-41.78%651.24K
-34.03%426.80K
58.96%1.12M
-28.00%646.92K
-32.31%703.72K
-17.02%898.46K
-24.44%1.04M
-6.77%1.08M
11.04%1.38M
--1.16M
--1.24M
16.52%620.68K
--532.70K
营业费用
-85.73%1.47M
-211.96%-5.84M
336.19%10.29M
34.80%5.22M
-39.82%2.36M
-9.47%3.87M
45.33%3.92M
39.46%4.28M
-21.51%2.70M
15.68%3.07M
32.62%3.44M
--2.65M
--2.59M
75.87%1.13M
--644.04K
折旧摊销及损耗
-33.30%68.54K
-28.32%100.50K
-6.56%102.75K
4.62%140.20K
-40.88%109.97K
-17.53%134.01K
1.68%186.00K
-18.06%162.49K
36.98%182.93K
--198.30K
--133.54K
----
----
103.83%29.75K
--14.60K
营业利润
93.17%-638.27K
253.33%6.83M
-712.64%-9.35M
-93.94%-4.46M
60.21%-1.15M
31.62%-2.30M
-348.45%-2.89M
-199.98%-3.36M
627.20%1.16M
-353.16%-1.12M
-116.64%-220.75K
--442.56K
--1.33M
-40.89%300.05K
--507.65K
净非营业利息收入（费用）
利息收入
--17.00
--9.10K
----
----
242.03%236.00
-99.99%182.00
-99.83%69.00
--1.77M
--40.65K
----
----
----
----
----
----
利息费用
-24.05%94.04K
99.76%136.79K
69.88%123.81K
875.47%68.48K
--72.88K
-98.84%7.02K
-100.00%0.00
--604.00K
--298.14K
----
----
----
----
----
----
出售证券收益
58.42%-88.45K
-233.43%-80.06K
31.75%-212.71K
19.76%-24.01K
---311.64K
98.72%-29.93K
100.00%0.00
---2.34M
---184.59K
----
----
----
----
----
----
特殊收入（费用）
----
-21.05%-422.92K
----
---349.39K
----
--0.00
----
100.00%0.00
----
---5.63M
----
----
----
----
----
其他非经营性收入（费用）
271.15%18.17K
-14.01%394.50K
-126.46%-10.62K
249.44%458.78K
-68.01%40.12K
-1241.00%-307.00K
-85.98%125.41K
79.53%-22.89K
2249.18%894.54K
-497.69%-111.85K
3969.82%38.08K
--28.13K
---984.00
-325.53%-12.05K
--5.34K
税前利润
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-68.07%-4.44M
45.97%-1.49M
42.03%-2.64M
-271.14%-2.77M
43.29%-4.56M
168.68%1.62M
-1831.95%-8.04M
-277.27%-2.35M
--464.01K
--1.33M
-42.62%286.73K
--499.75K
所得税
--0.00
----
----
-100.00%0.00
-100.00%0.00
100.55%2.37K
38.62%325.78K
-342.95%-427.70K
4649.28%235.02K
-20.43%-96.56K
-101.55%-5.17K
---80.17K
--332.41K
-16.07%104.86K
--124.94K
除税后利润
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
持续经营利润
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
归属于母公司的净利润
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
归属于普通股东的净利润
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
基本每股收益
98.72%-1.99
152.00%42.79
-32.37%-154.68
79.74%-82.30
85.31%-116.86
61.86%-406.17
-291.05%-795.36
77.59%-1.06K
125.18%416.32
-1253.48%-4.75K
-307.68%-1.65K
--412.00
--796.00
-51.46%122.56
--252.48
稀释每股收益
98.72%-1.99
152.00%42.79
-32.37%-154.68
79.74%-82.30
85.31%-116.86
61.86%-406.17
-291.05%-795.36
77.59%-1.06K
125.18%416.32
-1253.48%-4.75K
-307.68%-1.65K
--412.00
--796.00
-51.46%122.56
--252.48
每股派息
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
货币单位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
审计意见
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
